Evidence map›Paper›PMID 37587473›Full record

ArticleHarm reduction journal2023

Double counting of clients using services in Iran: implications for assessing the reach of harm reduction programs.

Fatemeh Tavakoli, Willi Mcfarland, Nima Ghalekhani, Mehrdad Khezri, Ali Akbar Haghdoost, Mohammad Mehdi Gouya, Marzieh Mahboobi, Ali Mohammad Hosseionpour, Ali Komasi, Mehdi Ghorbanian and 3 more

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

Fatemeh TavakoliHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Willi McfarlandDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Nima GhalekhaniHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Mehrdad KhezriHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Ali Akbar HaghdoostHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Mohammad Mehdi GouyaDepartment of Infectious Disease and Tropical Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Marzieh MahboobiIranian Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.
Ali Mohammad HosseionpourMashhad University of Medical Sciences, Mashhad, Iran.
Ali KomasiKermanshah University of Medical Sciences, Kermanshah, Iran.
Mehdi GhorbanianAlborz University of Medical Sciences, Alborz, Iran.
Nasim Nasiri MoghadamCenter for HIV/STI Control and Prevention, Kerman University of Medical Sciences, Kerman, Iran.
Maryam TaghipourShiraz University of Medical Sciences, Shiraz, Iran.
Hamid SharifiHIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. hsharifi@kmu.ac.ir.
Kerman University of Medical Sciences · IRIran University of Medical Sciences · IRJahrom University of Medical Sciences · IRKermanshah University of Medical Sciences · IRMashhad University of Medical Sciences · IRMinistry of Health and Medical Education · IRNew York University · USShiraz University of Medical Sciences · IRUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany people with high-risk sexual or injection behaviors use harm reduction services with different identities and are therefore counted more than once in client databases. This practice results in inaccurate statistics on the number of clients served and the effective reach of these services. This study aimed to determine the levels of double counting of clients of harm reduction services, including needle and syringe programs, condom distribution, HIV testing and counseling, and methadone maintenance in five cities in Iran.

methodsBetween September and March 2020, our study included 1630 clients, 115 staff of harm reduction centers, and 30 experts in the field of harm reduction in five cities in Iran. Clients of harm reduction services were asked about using harm reduction services multiple times at the same center or at different centers in the last year using different identities. Estimates of double counting derived from client responses were validated by panels of center staff and experts in harm reduction.

resultsSynthesizing data from clients, staff, and experts, the final estimates of double counting of clients using harm reduction services were: HIV testing 10% (95% confidence interval [CI] 0-15), needle and syringe programs 17% (95% CI 8.5-20), condom distribution programs 13% (95% CI 3-19), HIV/STI counseling 10% (95% CI 0-16), and methadone maintenance 7% (95% CI 2-10).

conclusionDouble counting of clients in harm reduction services in Iran is substantial. Data on clients reach by harm reduction services need to be corrected for double counting to improve program planning, client population size estimation, and efficient resource allocation.

Indexed as

HIV InfectionsSexually Transmitted DiseasesHarm ReductionHumansIranMethadoneMethadoneDouble countingDrug useHarm reductionHIVIran

Identifiers

PMID37587473
PMCPMC10429072
OpenAlexW4385874101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.